Eintrag weiter verarbeiten
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
Gespeichert in:
| Zeitschriftentitel: | Cancers |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Cancers, 12, 2020, 11, S. 3381 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
MDPI AG
|
| Schlagwörter: |
| author_facet |
Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. |
|---|---|
| author |
Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. |
| spellingShingle |
Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. Cancers Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers Cancer Research Oncology |
| author_sort |
taghizadeh, hossein |
| spelling |
Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. 2072-6694 MDPI AG Cancer Research Oncology http://dx.doi.org/10.3390/cancers12113381 <jats:p>Recurrent/metastatic (R/M) head and neck cancers bear a poor prognosis. In this analysis, we examined the efficacy and the outcome of targeted therapy recommendations based on the patients’ molecular tumor portrait after failure of all standard therapy options. In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular profile of 50 patients diagnosed with R/M head and neck cancer. Tumor samples of the patients were examined using next-generation sequencing panels of mutation hotspots, microsatellite instability (MSI) testing, and immunohistochemistry (IHC). In 31 cases (62.0% of all patients), a molecular-driven targeted therapy approach was recommended. Eventually, 14 patients (28%) received the suggested targeted therapy. Six of fourteen patients (43%) achieved stable disease conditions and four patients (29%) experienced a progressive disease. The median time to treatment failure was 2.8 months. Therapy recommendations were significantly more often issued for men (p = 0.037) than for women. This analysis demonstrated that precision medicine provided the basis for molecular-driven therapy recommendations in over half of the patients with advanced therapy refractory head and neck cancers, with significantly more therapy recommendations for men. Our analysis showed that although precision medicine approaches are implementable and feasible for the management of recurrent/metastatic head and neck cancers in daily clinical routine, there are major limitations and challenges that have to be overcome.</jats:p> Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers Cancers |
| doi_str_mv |
10.3390/cancers12113381 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIxMTMzODE |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIxMTMzODE |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
MDPI AG, 2020 |
| imprint_str_mv |
MDPI AG, 2020 |
| issn |
2072-6694 |
| issn_str_mv |
2072-6694 |
| language |
English |
| mega_collection |
MDPI AG (CrossRef) |
| match_str |
taghizadeh2020outcomeoftargetedtherapyrecommendationsformetastaticandrecurrentheadandneckcancers |
| publishDateSort |
2020 |
| publisher |
MDPI AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancers |
| source_id |
49 |
| title |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_unstemmed |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_full |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_fullStr |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_full_unstemmed |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_short |
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_sort |
outcome of targeted therapy recommendations for metastatic and recurrent head and neck cancers |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.3390/cancers12113381 |
| publishDate |
2020 |
| physical |
3381 |
| description |
<jats:p>Recurrent/metastatic (R/M) head and neck cancers bear a poor prognosis. In this analysis, we examined the efficacy and the outcome of targeted therapy recommendations based on the patients’ molecular tumor portrait after failure of all standard therapy options. In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular profile of 50 patients diagnosed with R/M head and neck cancer. Tumor samples of the patients were examined using next-generation sequencing panels of mutation hotspots, microsatellite instability (MSI) testing, and immunohistochemistry (IHC). In 31 cases (62.0% of all patients), a molecular-driven targeted therapy approach was recommended. Eventually, 14 patients (28%) received the suggested targeted therapy. Six of fourteen patients (43%) achieved stable disease conditions and four patients (29%) experienced a progressive disease. The median time to treatment failure was 2.8 months. Therapy recommendations were significantly more often issued for men (p = 0.037) than for women. This analysis demonstrated that precision medicine provided the basis for molecular-driven therapy recommendations in over half of the patients with advanced therapy refractory head and neck cancers, with significantly more therapy recommendations for men. Our analysis showed that although precision medicine approaches are implementable and feasible for the management of recurrent/metastatic head and neck cancers in daily clinical routine, there are major limitations and challenges that have to be overcome.</jats:p> |
| container_issue |
11 |
| container_start_page |
0 |
| container_title |
Cancers |
| container_volume |
12 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334575981035526 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:30:48.254Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Outcome+of+Targeted+Therapy+Recommendations+for+Metastatic+and+Recurrent+Head+and+Neck+Cancers&rft.date=2020-11-15&genre=article&issn=2072-6694&volume=12&issue=11&pages=3381&jtitle=Cancers&atitle=Outcome+of+Targeted+Therapy+Recommendations+for+Metastatic+and+Recurrent+Head+and+Neck+Cancers&aulast=Prager&aufirst=Gerald+W.&rft_id=info%3Adoi%2F10.3390%2Fcancers12113381&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334575981035526 |
| author | Taghizadeh, Hossein, Mader, Robert M., Müllauer, Leonhard, Fuereder, Thorsten, Kautzky-Willer, Alexandra, Prager, Gerald W. |
| author_facet | Taghizadeh, Hossein, Mader, Robert M., Müllauer, Leonhard, Fuereder, Thorsten, Kautzky-Willer, Alexandra, Prager, Gerald W., Taghizadeh, Hossein, Mader, Robert M., Müllauer, Leonhard, Fuereder, Thorsten, Kautzky-Willer, Alexandra, Prager, Gerald W. |
| author_sort | taghizadeh, hossein |
| container_issue | 11 |
| container_start_page | 0 |
| container_title | Cancers |
| container_volume | 12 |
| description | <jats:p>Recurrent/metastatic (R/M) head and neck cancers bear a poor prognosis. In this analysis, we examined the efficacy and the outcome of targeted therapy recommendations based on the patients’ molecular tumor portrait after failure of all standard therapy options. In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular profile of 50 patients diagnosed with R/M head and neck cancer. Tumor samples of the patients were examined using next-generation sequencing panels of mutation hotspots, microsatellite instability (MSI) testing, and immunohistochemistry (IHC). In 31 cases (62.0% of all patients), a molecular-driven targeted therapy approach was recommended. Eventually, 14 patients (28%) received the suggested targeted therapy. Six of fourteen patients (43%) achieved stable disease conditions and four patients (29%) experienced a progressive disease. The median time to treatment failure was 2.8 months. Therapy recommendations were significantly more often issued for men (p = 0.037) than for women. This analysis demonstrated that precision medicine provided the basis for molecular-driven therapy recommendations in over half of the patients with advanced therapy refractory head and neck cancers, with significantly more therapy recommendations for men. Our analysis showed that although precision medicine approaches are implementable and feasible for the management of recurrent/metastatic head and neck cancers in daily clinical routine, there are major limitations and challenges that have to be overcome.</jats:p> |
| doi_str_mv | 10.3390/cancers12113381 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9jYW5jZXJzMTIxMTMzODE |
| imprint | MDPI AG, 2020 |
| imprint_str_mv | MDPI AG, 2020 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2072-6694 |
| issn_str_mv | 2072-6694 |
| language | English |
| last_indexed | 2024-03-01T14:30:48.254Z |
| match_str | taghizadeh2020outcomeoftargetedtherapyrecommendationsformetastaticandrecurrentheadandneckcancers |
| mega_collection | MDPI AG (CrossRef) |
| physical | 3381 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | MDPI AG |
| record_format | ai |
| recordtype | ai |
| series | Cancers |
| source_id | 49 |
| spelling | Taghizadeh, Hossein Mader, Robert M. Müllauer, Leonhard Fuereder, Thorsten Kautzky-Willer, Alexandra Prager, Gerald W. 2072-6694 MDPI AG Cancer Research Oncology http://dx.doi.org/10.3390/cancers12113381 <jats:p>Recurrent/metastatic (R/M) head and neck cancers bear a poor prognosis. In this analysis, we examined the efficacy and the outcome of targeted therapy recommendations based on the patients’ molecular tumor portrait after failure of all standard therapy options. In this single-center, real-world retrospective analysis of our platform for precision medicine, we analyzed the molecular profile of 50 patients diagnosed with R/M head and neck cancer. Tumor samples of the patients were examined using next-generation sequencing panels of mutation hotspots, microsatellite instability (MSI) testing, and immunohistochemistry (IHC). In 31 cases (62.0% of all patients), a molecular-driven targeted therapy approach was recommended. Eventually, 14 patients (28%) received the suggested targeted therapy. Six of fourteen patients (43%) achieved stable disease conditions and four patients (29%) experienced a progressive disease. The median time to treatment failure was 2.8 months. Therapy recommendations were significantly more often issued for men (p = 0.037) than for women. This analysis demonstrated that precision medicine provided the basis for molecular-driven therapy recommendations in over half of the patients with advanced therapy refractory head and neck cancers, with significantly more therapy recommendations for men. Our analysis showed that although precision medicine approaches are implementable and feasible for the management of recurrent/metastatic head and neck cancers in daily clinical routine, there are major limitations and challenges that have to be overcome.</jats:p> Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers Cancers |
| spellingShingle | Taghizadeh, Hossein, Mader, Robert M., Müllauer, Leonhard, Fuereder, Thorsten, Kautzky-Willer, Alexandra, Prager, Gerald W., Cancers, Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers, Cancer Research, Oncology |
| title | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_full | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_fullStr | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_full_unstemmed | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_short | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| title_sort | outcome of targeted therapy recommendations for metastatic and recurrent head and neck cancers |
| title_unstemmed | Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.3390/cancers12113381 |